Background The phase 3 FUTURE 5 trial (NCT02404350) showed the clinical and radiographical efficacy of secukinumab in patients with psoriatic arthritis. This analysis aimed to assess effect on patient-reported outcomes (PROs). Methods was a 3, multicentre, parallel-group randomised which who were 18 years old or older, met classification criteria for arthritis at screening, had symptoms moderat...